Wall Street analysts predict that Medidata Solutions Inc (NASDAQ:MDSO) will report $140.76 million in sales for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Medidata Solutions’ earnings, with the highest sales estimate coming in at $141.34 million and the lowest estimate coming in at $140.20 million. Medidata Solutions posted sales of $124.47 million during the same quarter last year, which would indicate a positive year over year growth rate of 13.1%. The business is expected to announce its next quarterly earnings results on Thursday, February 8th.

On average, analysts expect that Medidata Solutions will report full-year sales of $140.76 million for the current fiscal year, with estimates ranging from $544.50 million to $546.00 million. For the next fiscal year, analysts expect that the firm will report sales of $641.57 million per share, with estimates ranging from $635.19 million to $650.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that follow Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02. The business had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period last year, the company posted $0.28 earnings per share.

A number of research firms have commented on MDSO. Jefferies Group restated a “hold” rating and issued a $78.00 price target on shares of Medidata Solutions in a report on Tuesday, August 22nd. TheStreet cut shares of Medidata Solutions from a “b” rating to a “c+” rating in a report on Thursday, December 14th. Royal Bank of Canada initiated coverage on shares of Medidata Solutions in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $82.00 price target for the company. Deutsche Bank initiated coverage on shares of Medidata Solutions in a report on Friday, December 8th. They set a “buy” rating and a $78.00 price objective for the company. Finally, Dougherty & Co initiated coverage on shares of Medidata Solutions in a report on Thursday, November 2nd. They set a “neutral” rating for the company. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Medidata Solutions presently has a consensus rating of “Buy” and an average target price of $84.54.

In related news, CEO Tarek Sherif sold 200,000 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $68.76, for a total transaction of $13,752,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Rouven Bergmann sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $65.40, for a total transaction of $130,800.00. Following the transaction, the chief financial officer now directly owns 91,775 shares in the company, valued at $6,002,085. The disclosure for this sale can be found here. Insiders have sold 237,010 shares of company stock valued at $16,305,136 over the last quarter. Corporate insiders own 5.80% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDSO. Russell Investments Group Ltd. lifted its position in shares of Medidata Solutions by 80.5% during the second quarter. Russell Investments Group Ltd. now owns 28,574 shares of the company’s stock valued at $2,235,000 after purchasing an additional 12,743 shares in the last quarter. Sei Investments Co. lifted its position in shares of Medidata Solutions by 5.4% during the second quarter. Sei Investments Co. now owns 37,844 shares of the company’s stock valued at $2,960,000 after purchasing an additional 1,925 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Medidata Solutions by 3.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 236,378 shares of the company’s stock valued at $18,485,000 after purchasing an additional 7,651 shares in the last quarter. First Trust Advisors LP bought a new position in shares of Medidata Solutions during the second quarter valued at about $2,772,000. Finally, Rhumbline Advisers lifted its position in shares of Medidata Solutions by 1.2% during the second quarter. Rhumbline Advisers now owns 112,429 shares of the company’s stock valued at $8,792,000 after purchasing an additional 1,363 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Shares of Medidata Solutions (MDSO) opened at $65.70 on Wednesday. The company has a quick ratio of 3.37, a current ratio of 1.29 and a debt-to-equity ratio of 0.61. The company has a market cap of $3,844.98, a price-to-earnings ratio of 79.24, a price-to-earnings-growth ratio of 4.08 and a beta of 1.69. Medidata Solutions has a twelve month low of $47.77 and a twelve month high of $85.92.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/20/medidata-solutions-inc-mdso-expected-to-announce-quarterly-sales-of-140-76-million.html.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.